Alzchem Reports Growth in Sales and Profitability

Alzchem Group AG, a global specialty chemicals company, announced a 4% increase in sales, reaching EUR 443.8 million, and an 8% rise in EBITDA to EUR 93.2 million for the first nine months of 2026. The EBITDA margin improved from 20.3% to 21.0%. This growth is attributed to high demand for high-quality ingredients, particularly in the nutrition and defense sectors. Despite higher energy and raw material costs, the consolidated result rose to EUR 48.4 million.

The Specialty Chemicals segment saw an 11% sales increase, driven by demand for premium creatine brands. The Basics & Intermediates segment experienced a sales decline, affected by subdued demand and higher costs, though it returned to positive EBITDA in the third quarter.

Alzchem is expanding capacity in response to growth market demands, with new facilities in Germany and planned expansion in the U.S. The company maintains its forecast for the year, expecting sales of EUR 600 million and EBITDA of EUR 126 million.